-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2021 to Q2 2024.
- Immix Biopharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$4.7M, a 26.4% decline year-over-year.
- Immix Biopharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$20.2M, a 74.5% decline year-over-year.
- Immix Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$16.1M, a 96.4% decline from 2022.
- Immix Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$8.22M, a 508% decline from 2021.
- Immix Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$1.35M, a 198% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)